Medical/Pharmaceuticals

CARiNG Pharmacy Awarded Gold in Esteemed Putra Aria Brand Awards 2023 in Retail Category

KUALA LUMPUR, Malaysia, Feb. 5, 2024 /PRNewswire/ -- CARiNG Pharmacy proudly announced its victory at the second edition of the prestigious Putra Aria Brand Awards 2023, securing the coveted Gold Award in the Retail Category in recognition of its outstanding contributions to the retail industry. ...

2024-02-05 17:31 1605

Celebrating a Legacy of Care - Pantai Hospital Kuala Lumpur Celebrates 50 Years of Excellence in Healthcare and Unveils Its Future Vision with Gala Dinner

KUALA LUMPUR, Malaysia, Feb. 5, 2024 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone with its 50th Anniversary Gala Dinner, an event that highlighted the hospital's impressive legacy and future ambitions in the healthcare sector.

2024-02-05 17:01 2078

Innovent Announces Retirement of CFO and Appointment of New CFO

ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other ...

2024-02-05 16:45 2894

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery. The company has made remarkable technological breakthroughs in developing highly miniaturized and flexible robot...

2024-02-05 09:53 1845

Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy

* ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. * Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stag...

2024-02-05 08:00 1487

Blossoming Flowers at the Top of the Biopharmaceutical Tree -- Reflections on the Flourishing of Sanyou's 4C Business

SHANGHAI, Feb. 2, 2024 /PRNewswire/ -- In 1996, MDS Pharma Service invested in and established the first true Contract Research Organization (CRO) inChina, dedicated to clinical trial business for new drugs. This marked the official launch of the CRO industry inChina. The concept of CRO originat...

2024-02-03 08:00 2439

Mindvalley Launches First Fully Immersive Meditation and Personal Development App on Apple's Vision Pro

Mindvalley is solo immersive Personal Development App Included on visionOS App Store  KUALA LUMPUR, Malaysia and LONDON and NEW YORK and LOS ANGELES, Feb. 3, 2024 /PRNewswire/ --Mindvalley, the leading personal growth platform, is thrilled to announce the launch of its groundbreaking fully immer...

2024-02-03 03:19 4110

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-prote...

2024-02-02 22:22 2843

Inmagene Exercises Option to Obtain Exclusive Worldwide License for IMG-007 and IMG-004 from HUTCHMED

* Inmagene exercised its option under the previously announced collaboration agreement to obtain an exclusive, royalty-bearing license for IMG-007, an anti-OX40 monoclonal antibody (mAb) and IMG-004, a Bruton Tyrosine Kinase (BTK) inhibitor * Inmagene retains rights to develop and commerciali...

2024-02-02 22:00 2217

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on Febru...

2024-02-02 21:30 2346

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

JINAN, China, Feb. 2, 2024 /PRNewswire/ -- On January 29th, the results of the phase II study on Qilu Pharmaceutical's novel anticancer drug iparomlimab and tuvonralimab (QL1706) were published online inSignal Transduction and Targeted Therapy (Impact Factor=39.3). The study investigated the use ...

2024-02-02 17:34 1760

Fapon and Bio Farma Sign MOU for Medical Innovations

DONGGUAN, China, Feb. 2, 2024 /PRNewswire/ -- On February 1, 2024, Fapon, a global leading life science company, andBio Farma, a state-owned pharmaceutical holding company inIndonesia specializing in vaccines, life science products, and other pharmaceuticals, signed a memorandum of understanding ...

2024-02-02 16:30 2560

Xinhua Silk Road: Pien Tze Huang, Beijing Tong Ren Tang agree to boost bilateral cooperation, promote high-quality development of TCM

BEIJING, Feb. 2, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. (Pien Tze Huang) signed a cooperation agreement with Beijing Tong Ren Tang (TRT) Group during the First Conference of Partners of Tong Ren Tang, which was held inBeijing from January 17 to 19. 

2024-02-02 11:14 2560

NABR Files Expanded Petition Challenging the Listing of Long-Tailed Macaques by the IUCN

WASHINGTON, Feb. 2, 2024 /PRNewswire/ -- Working with recognized, independent scientists, the National Association for Biomedical Research (NABR) filed an expanded petition today with the International Union for Conservation of Nature (IUCN) challenging the designation of the long-tailed macaque ...

2024-02-02 09:01 2113

Biosyngen Announces FDA Fast Track Designation for BST02 in Treatment of Liver Cancer

SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of liver cancer, including hepatocellular carcinoma and...

2024-02-01 17:41 2349

EMA Aesthetics Announces a Long-Term Strategic and Equity Partnership with ROHTO Pharmaceutical, Signalling ROHTO's Acceleration into the Global Aesthetics Market

DUBLIN, Feb. 1, 2024 /PRNewswire/ -- EMA Aesthetics (www.emaaesthetics.com ) a global aesthetics company headquartered inDublin, is delighted to announce a strategic and equity partnership with ROHTO Pharmaceutical ( www.rohto.co.jp/global

2024-02-01 16:00 2288

NX Netherlands Receives IATA CEIV Pharma Certification for Its Warehouse Near Amsterdam Airport Schiphol

TOKYO, Feb. 1, 2024 /PRNewswire/ -- Nippon Express (Nederland) B.V. (hereinafter "NX Netherlands"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired CEIV Pharma certification (*), a quality certification for pharmaceutical transport established by the International Air Transport As...

2024-02-01 14:00 1962

2024 Global Appeal Calls for Well-Informed Public to 'Break Chains of Discrimination' against Leprosy

TOKYO, Feb. 1, 2024 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative has partnered with the World Health Organization to co-host the launch of the 2024 Global Appeal to end stigma and discrimination against persons affected by leprosy at WHO headquarters inGeneva on January 31, 2024...

2024-02-01 14:00 1620

Promising Clinical Results on the World's First Use of BCMA CAR-T to Treat Immune Mediated Necrotizing Myopathy (IMNM) Published on the Proceedings of the National Academy of Sciences (PNAS)

SHANGHAI, NANJING, China and SAN JOSE, Calif., Jan. 31, 2024 /PRNewswire/ -- On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results using the fully human B ...

2024-02-01 11:07 1931

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation

SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Feb. 1, 2024 /PRNewswire/ -- SoniVie , an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive diso...

2024-02-01 01:52 1735
1 ... 979899100101102103 ... 611

Week's Top Stories